AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 152 filers reported holding AKERO THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 1.85 and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $11,765,616 | +41.9% | 232,614 | +31.0% | 0.02% | +47.1% |
Q2 2023 | $8,292,798 | +23.5% | 177,614 | +1.2% | 0.02% | +13.3% |
Q1 2023 | $6,717,079 | -24.9% | 175,564 | +7.5% | 0.02% | -25.0% |
Q4 2022 | $8,946,867 | +54.5% | 163,264 | -4.0% | 0.02% | +42.9% |
Q3 2022 | $5,790,000 | +756.5% | 170,034 | +137.8% | 0.01% | +600.0% |
Q2 2022 | $676,000 | +88.3% | 71,491 | +182.7% | 0.00% | +100.0% |
Q1 2022 | $359,000 | -32.9% | 25,285 | 0.0% | 0.00% | 0.0% |
Q4 2021 | $535,000 | -5.3% | 25,285 | 0.0% | 0.00% | 0.0% |
Q3 2021 | $565,000 | -10.0% | 25,285 | 0.0% | 0.00% | 0.0% |
Q2 2021 | $628,000 | -14.3% | 25,285 | 0.0% | 0.00% | -50.0% |
Q1 2021 | $733,000 | +12.4% | 25,285 | 0.0% | 0.00% | +100.0% |
Q4 2020 | $652,000 | +9.6% | 25,285 | +30.9% | 0.00% | -50.0% |
Q3 2020 | $595,000 | -12.2% | 19,321 | -29.0% | 0.00% | 0.0% |
Q2 2020 | $678,000 | +109.3% | 27,202 | +78.2% | 0.00% | +100.0% |
Q1 2020 | $324,000 | -38.8% | 15,269 | -35.9% | 0.00% | 0.0% |
Q4 2019 | $529,000 | – | 23,823 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Skorpios Trust | 3,271,829 | $179,296 | 57.03% |
Redmile Group, LLC | 2,632,912 | $144,283,578 | 5.90% |
Avidity Partners Management LP | 3,825,000 | $209,610,000 | 4.54% |
COMMODORE CAPITAL LP | 537,076 | $29,432 | 4.44% |
Atlas Venture Life Science Advisors, LLC | 594,251 | $32,564,955 | 3.92% |
Paradigm Biocapital Advisors LP | 604,544 | $33,129,011 | 3.89% |
Yiheng Capital Management, L.P. | 1,468,905 | $80,495,994 | 3.56% |
Altium Capital Management LP | 125,000 | $6,850,000 | 3.48% |
Tri Locum Partners LP | 128,851 | $7,061,000 | 2.86% |
SILVERARC CAPITAL MANAGEMENT, LLC | 172,100 | $9,431,080 | 2.70% |